Affimer Therapeutics Yield Positive Results
News Sep 22, 2016
Avacta Group plc announce positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules. The results meaningfully de-risk the development of the technology as a therapeutic platform; demonstrating that Affimer molecules possess good drug-like properties in terms of efficacy, serum half-life and tolerability.
Two parallel in-vivo pre-clinical studies have been completed. The first, a pharmacokinetics study looking at both human and mouse PD-L1 Affimer inhibitors1engineered as Fc fusions2, showed that Affimer molecules have good in-vivo serum half-lives and are well tolerated at the clinically relevant doses used in the study.
The second was an efficacy study using a mouse PD-L1 specific Affimer molecule in a syngeneic tumour model3. In this study the Affimer PD-L1 inhibitor produced a statistically significant reduction in tumour growth demonstrating the bioavailability and functionality of the Affimer molecule in tumours in-vivo. No adverse effects were observed.
Alastair Smith, Avacta Group Chief Executive commented: “These results demonstrate that Affimer molecules possess good in-vivo drug-like properties in terms of efficacy, serum half-life and tolerability which is a hugely important milestone in the development and de-risking of the technology as a therapeutic platform. From the initial screening process for the Affimer binders we have been able to rapidly progress to evaluating them in in-vivo models, highlighting another major advantage of the technology. We are very encouraged by these initial positive results and will continue to focus on developing both our internal and partnered therapeutic programs towards clinical validation.”
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Daily Dose of Viagra Could Reduce Colorectal Cancer RiskNews
A small, daily dose of Viagra significantly reduces colorectal cancer risk in an animal model that is genetically predetermined to have the third leading cause of cancer death, scientists report.READ MORE
Could Extracellular Vesicles be Personalized Drug Delivery Vehicles?News
Creating enough nanovesicles to inexpensively serve as a drug delivery system may be as simple as putting the cells through a sieve, according to an international team of researchers who used mouse autologous — their own — immune cells to create large amounts of fillable nanovesicles to deliver drugs to tumors in mice.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018